VADUZ, Liechtenstein, May 8, 2024 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the first quarter 2024 at 15:00 CEST on May 15. The interim report for the first quarter will be published at 8:00 a.m. CEST on the same day.
The presentation will be in English via an audiocast with teleconference:
If you wish to participate via webcast, please use the following link:
-- https://ir.financialhearings.com/implantica-q1-report-2024
[https://c212.net/c/link/?t=0&l=en&o=4161645-1&h=1683772998&u=https%3A%2
F%2Fir.financialhearings.com%2Fimplantica-q1-report-2024&a=https%3A%2F%2
Fir.financialhearings.com%2Fimplantica-q1-report-2024]
If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.
-- https://conference.financialhearings.com/teleconference/?id=50049901
[https://c212.net/c/link/?t=0&l=en&o=4161645-1&h=185764419&u=https%3A%2F
%2Fconference.financialhearings.com%2Fteleconference%2F%3Fid%3D50049901&
a=https%3A%2F%2Fconference.financialhearings.com%2Fteleconference%2F%3Fi
d%3D50049901]
Speakers:
-- CEO Peter Forsell
-- CFO Andreas Öhrnberg
-- Chief Corporate Affairs Officer Nicole Pehrsson
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com [mailto:nicole.pehrsson@implantica.com]
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, info@fnca.se [mailto:info@fnca.se]
The information was sent for publication, through the agency of the contact person set out above, on May 8, 2024 at 2:30 p.m. CEST.
About Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop(TM), is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market . Visit www.implantica.com [https://c212.net/c/link/?t=0&l=en&o=4161645-1&h=976076220&u=http%3A%2F%2Fwww.implantica.com%2F&a=www.implantica.com] for further information.
This information was brought to you by Cision http://news.cision.com [https://c212.net/c/link/?t=0&l=en&o=4161645-1&h=1676741979&u=http%3A%2F%2Fnews.cision.com%2F&a=http%3A%2F%2Fnews.cision.com]
https://news.cision.com/implantica/r/implantica-presents-the-first-quarter-2024-on-may-15-at-15-00-cest,c3975946 [https://c212.net/c/link/?t=0&l=en&o=4161645-1&h=176755463&u=https%3A%2F%2Fnews.cision.com%2Fimplantica%2Fr%2Fimplantica-presents-the-first-quarter-2024-on-may-15-at-15-00-cest%2Cc3975946&a=https%3A%2F%2Fnews.cision.com%2Fimplantica%2Fr%2Fimplantica-presents-the-first-quarter-2024-on-may-15-at-15-00-cest%2Cc3975946]
The following files are available for download:
https://mb.cision.com/Main/19732/3975946/2786465.pdf Implantica presents the first quarter 2024 on May 15 at 15:00 CEST
View original content:https://www.prnewswire.co.uk/news-releases/implantica-presents-the-first-quarter-2024-on-may-15-at-1500-cest-302139840.html [https://www.prnewswire.co.uk/news-releases/implantica-presents-the-first-quarter-2024-on-may-15-at-1500-cest-302139840.html]
Implantica